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doi:10.1016/j.asjsur.2012.02.001Summary Purpose: Benign prostatic hyperplasia is a common disease affecting older males.
As obesity becomes an increasing problem worldwide, its role in prostatic hypertrophy has
been discussed recently. The purpose of this study is to evaluate the relationship between
waist circumferences and prostatic hyperplasia in Taiwan.
Methods: There were 539 men enrolled in the study who had health examinations at the
Healthcare Center of Chang Gung Memorial Hospital; 53 were excluded because of history of
conditions affecting prostatic volume. Their anthropometry was measured and serum
prostate-specific antigen (PSA) levels as well as lipid profiles were analyzed. Prostate volume
was measured by transrectal ultrasonography performed by experienced urologists.
Results: The mean prostate volume was 26.43 mL, whereas mean body mass index (BMI) was
25.27 kg/m2 and mean waist circumference (WC) was 90.81 cm. By age-adjusted logistic
regression, PSA > 4 ng/mL, WC  90 cm, and BMI > 24 kg/m2 are associated with increased
risk of developing prostatic hyperplasia; only WC  90 cm can be validated by multiple
logistic regression. Further analysis of obesity patterns showed that abdominal over-
weight/obesity places patients at increased risk independently rather than high WC or high
BMI alone.of Urology, Chang-Gung Memorial Hospital, No. 5 Fu-Hsing Street, Gueishan, Taoyuan County 33305,
(Y.-J. Chiang).
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164 H.-H. Wang et al.Table 1 Prevalence of BPH/obe
Age group Populationa
20e29 1,868,538
30e39 1,869,403
40e49 1,895,635
50e59 1,523,007
60e69 754,700
70e79 535,693
80 260,861
a Midyear population is the averag
b Number of men with BPH (ICD co
c Defined as number of patients di
d Number of men with obesity (ICD
Report.3 BPHZ benign prostatic hypConclusions: Study results showed that waist circumference  90 cm is an independent risk
factor of prostatic hyperplasia in Taiwan. Men with abdominal overweight/obesity (WC
 90 cm and BMI > 24 kg/m2) have a twofold risk of developing prostatic hyperplasia.
Copyright ª 2012, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Benign prostatic hyperplasia (BPH) is a common disease
affecting middle-aged and older males that accounted for
4.4 million outpatient visits as a primary diagnosis in the
year 2000 in the United States.1 Approximately 24% of white
men 50 to 79 years old were estimated to have BPH.1
According to the 2008 national statistical data published
by Ministry of the Interior2 and Department of Health,3
Taiwan’s BPH prevalence, defined as clinic visits or hospi-
talizations with a primary diagnosis of BPH per midyear
population, is 14.71% in men 60 to 69 years of age and
26.90% in men 70 to 79 years of age (Table 1). Prostatic
hyperplasia causes both obstructive and irritative symptoms
interfering both quality of life and productivity of affected
men. The medical costs for BPH treatment were $2.36
billion New Taiwan dollars in the year 2008, accounting for
0.51% of the annual national health insurance budget in
Taiwan.3 These costs did not include the money for the self-
paid instruments used in BPH endoscopic surgeries, which
are not supported by the national health insurance system.
The pathogenesis of BPH is not well understood. Aging,
androgens, estrogens, growth factors, inflammation, and
some modifiable risk factors including obesity and diabetes
have been reported to play important roles in the etiology
of BPH.4e6 In the Baltimore Longitudinal Study of Aging
(BLSA), body mass index (BMI) greater than 35 mg/kg2 is
associated with increased risk of enlarged prostate (40 cc
or greater).7 Giovannucci et al.8 reported more surgical
procedures to treat BPH in males with waist circumference
(WC) greater than 109 cm. The third National Health and
Nutritional Examination Survey (NHANES-III) suggested
WC greater than 102 cm is associated with an increased
incidence of lower urinary tract symptoms (LUTS).9 This
evidence indicates a positive correlation between male WC
and prostate volume (PV).sity as primary diagnosis in Taiw
Patients with BPHb P
711 0
3643 0
25,691 1
83,055 5
113,138 1
143,384 2
84,685 3
e of the 2007 and 2008 populatio
de 600) as the primary diagnosis
vided by midyear population.
code 278) as the primary diagno
erplasia.Because PV predicts BPH-related treatment outcomes,10
it is important to acknowledge PV in the management of
patients with BPH. Transrectal ultrasonography (TRUS) of
the prostate, described by Terris et al.,11 is by far the most
accurate and reproducible method for measuring PV. We
observed the same trend that men with greater WC tend to
have an enlarged prostate while performing TRUS at our
hospital. This preliminary report examines the relationship
between WC and PV in Taiwanese adult men.
2. Methods
2.1. Patients
During the period between January and May 2009, 539 men
completed advanced health examination including TRUS of
the prostate at Healthcare Center of Chang Gung Memorial
Hospital. Fifty-three of them were excluded from the study
because of a history of prostate surgery (15), prostate
malignancy (9), or taking 5-alpha reductase inhibitors (29),
which might affect the size of the prostate. A total of 486
men, age 33 to 93 years, were included in this cross-
sectional study, which is approved by the institutional
review board of the hospital.
2.2. Measurement
Body weight and height were measured and recorded at
registration, and WCs were measured at the narrowest point
between the lowest rib and the uppermost lateral border of
the iliac crest. BMI was calculated as body weight in kilo-
grams divided by the square of the patient’s height in
meters. We use national standards provided by the Bureau
of Health Promotion to define BMI greater than 24 kg/m2 as
overweight/obesity and WC larger or equal to 90 cm asanese men.
revalencec Patients with obesityd Prevalencec
.04% 3435 0.18%
.19% 4564 0.24%
.36% 4396 0.23%
.45% 3596 0.24%
4.99% 1525 0.20%
6.77% 683 0.13%
2.46% 191 0.07%
ns, data from the 2008 Annual Population Statistics Report.2
.
sis, data from the 2008 Annual National Health Insurance Annual
Waist circumference and BPH 165above normal. Fasting blood sugar, prostate-specific antigen
(PSA), triglyceride, cholesterol, and high-density lipopro-
tein (HDL) levels were checked before proceeding to TRUS
to avoid transducer’s influence on the serum PSA level.
2.3. Transrectal ultrasonography
Five experienced urologists (KJL, MLH, YC, HCH, and YCH),
who did not have the information about the aim of this study,
performed TRUS of the prostate gland. A 7 - MHz rectal
transducer (VT-TRT5000) was used with an ultrasound
scanner (HDI5000, Philips, the Netherlands) with the method
described by Terris et al.11 Diameters on three axes were
recorded and the volume of prostate was calculated with the
spheroid formula: p/6 (diameter 1) (diameter 2) (diameter
3). Prostatic hyperplasia was defined as a volume exceeding
20 mL, a commonly used parameter of clinical BPH criteria.12
2.4. Statistical analysis
Statistical analyses were performed using SAS statistical
package (SAS for Windows version 9.2, SAS Institute Inc.,
Cary, NC, USA.). Odds ratios (ORs) were calculated using
binary logistic regression analysis to evaluate the associa-
tion between these variables and prostatic hyperplasia,
which was defined as a PV > 20 mL, after adjusting for age
in 10-year intervals. Multiple logistic regression also was
used as a multivariate analysis model for prostatic hyper-
plasia. Statistical significance was defined as p< 0.05; all
tests were two-sided.
3. Results
3.1. Patient characteristics
The characteristics of these 486 men are listed in Table 2.
The age distribution of these patients was as follows: 18Table 2 Basic profiles.
Parameter
(unit)
10th
percentile
90th
percentile
Mean Standard
deviation
Height (cm) 160.60 174.10 167.42 5.61
Weight (kg) 57.80 84.50 70.94 10.96
BMI (kg/m2) 21.07 29.75 25.27 3.42
WC (cm) 80 102 90.81 9.34
PV (mL) 16.81 38.09 26.43 10.09
PSA (ng/mL) 0.39 3.11 1.52 2.77
Fasting sugar
(mg/dL)
84 118 101.10 30.52
TG (mg/dL) 70 240 146.01 81.19
Chol (mg/dL) 160 244 200.74 34.39
HDL (mg/dL) 35.03 66.97 49.80 13.02
Chol/HDL 2.84 5.74 4.31 2.01
LDL/HDL 1.53 3.62 2.62 1.05
BMIZ body mass index; CholZ cholesterol; HDLZ high-density
lipoprotein; LDLZ low-density lipoprotein; PSAZ prostate-
specific antigen; PVZ prostate volume; TGZ triglyceride;
WCZwaist circumference.men (3.7%) in their 30s; 125 (25.7%) in their 40s; 192 (39.5%)
in their 50s; 100 (20.6%) in their 60s; and 51(10.5%) older
than 70 years. The mean PSA level was 1.52 ng/mL and the
mean PV was 26.43 mL, compatible with that of most
patients older than 50 years who are prone to having an
enlarged prostate. Their mean BMI was 25.27 kg/m2; mean
WC, 90.81 cm; and mean cholesterol level, 200.74 mg/dL;
all values are slightly above the recommended thresholds
(24 kg/m2, 90 cm, and 200 mg/dL, respectively).
3.2. Association between PV and variables
We used age-adjusted regression to examine the ORs of
each variable to evaluate their risks on BPH, defined as PV
exceeding 20 mL (Table 3). The data showed that men with
elevated PSA level (OR 5.507, 95% CI 1.187-21.547,
pZ 0.028), large WC (OR 1.565, 95% CI 1.031-2.377,
pZ 0.036), BMI greater than 24 kg/m2 (OR 1.877, 95% CI
1.242-2.838, pZ 0.003), and aging (p< 0.001 in each 10-
year age interval) are associated with higher risk of
developing prostate hyperplasia; serum fasting blood sugar,
triglyceride, cholesterol, and HDL levels are not related to
enlarged prostate. By multivariate analysis of these signif-
icant variables, we found that only large WC (OR 1.737,
95% CI 1.007-2.997, pZ 0.047) and age can significantly
increase the risk of prostatic hyperplasia independently; on
the contrary, high PSA (OR 3.339, 95% CI 0.741-15.04,
pZ 0.116) or BMI (OR 1.224, 95% CI 0.703-2.131, pZ 0.475)
were not independent risk factor (data not shown).
3.3. Association between PV and obesity indices
To avoid possible false interpretation of obesity by WC or
BMI value alone, we divided these men into four groups
according to WC and BMI status, including normal WC
and BMI (BMI  24 kg/m2 and WC < 90 cm), high WC aloneTable 3 Age-adjusted odds ratios of prostatic hyperplasia.a
Variable N Odds
ratio
95% CI p
value
PSA  4 ng/mL 456 1 (reference)
PSA > 4 ng/mL 30 5.507 1.187e21.547 0.028
WC < 90 cm 216 1 (reference)
WC  90 cm 270 1.565 1.031e2.377 0.036
BMI  24 kg/m2 175 1 (reference)
BMI > 24 kg/m2 311 1.877 1.242e2.838 0.003
Glucose < 110 mg/dL 407 1 (reference)
Glucose 110 mg/dL 79 1.084 0.618e1.901 0.779
TG < 150 mg/dL 302 1 (reference)
TG  150 mg/dL 184 1.300 0.846e1.998 0.232
Chol < 200 mg/dL 248 1 (reference)
Chol  200 mg/dL 238 1.010 0.671e1.521 0.961
HDL  40 mg/dL 385 1 (reference)
HDL< 40 mg/dL 101 1.190 0.709e1.997 0.510
BMIZ body mass index; CholZ cholesterol; CIZ confidence
interval; HDLZ high-density lipoprotein; PSAZ prostate-specific
antigen; TGZ triglyceride; WCZwaist circumference.
a Adjusted for age in 10-year categories by multiple logistic
regression, hyperplasia defined as prostate volume > 20 mL.
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> 24 kg/m2 and WC < 90 cm), and abdominal overweight/
obesity (BMI > 24 kg/m2 and WC  90 cm). Next, we
analyzed the ORs of these obesity indices with age intervals
and PSA level. In this age-adjusted multivariate analysis
model, the only independent risk factor of PV exceeding
20 mL is abdominal overweight/obesity (OR 2.112, 95% CI
1.284-3.474, pZ 0.003), as shown in Table 4. Elevated PSA
level (OR 3.339, 95% CI 0.741-15.040, pZ 0.116), large WC
alone (OR 1.210, 95% CI: 0.458-3.199, pZ 0.701), or high
BMI alone (OR 1.049, 95% CI 0.546-2.014, pZ 0.886) cannot
increase the risk of BPH independently.4. Discussion
The numbers of obese individuals are increasing in both
developed and developing countries. This finding may be
related to an increase in high-calorie diets and less physical
activity. Obesity increases the risk of cardiovascular
diseases, type 2 diabetes, hypertension, and dyslipidemia
and leads to increased mortality.13 Average medical costs
are also significantly higher in obese individuals than in
persons of normal weight.14 However, obesity is often
underdiagnosed, as indicated by an average primary diag-
nosis prevalence of 0.21% in the National Health Insurance
Annual Report (Table 1), whereas the 2005-2008 Nutrition
and Health Survey in Taiwan (NAHSIT) showed 29% of men
have a WC  90 cm and 51% of men are overweight/obese
(BMI > 24 kg/m2).15 This explains how obesity is rarely
taken into primary consideration in clinics or before
hospitalization. In our study, there are 270 men (55.6%)
with WC  90 cm and 311 men (64%) with BMI > 24 kg/m2
(Table 3), values that are above the national average. This
finding might reflect these observed men have better
socioeconomic status to pay for the examinations; resulting
in an increased likelihood of developing obesity.
The etiology of BPH is multifactorial, and obesity and its
related states have long been associated with BPH.4e7Table 4 Multivariate adjusteda odds ratios of prostatic
hyperplasia.b
Variable N Odds
ratio
95% CI p
value
PSA  4 ng/mL 456 1 (reference)
PSA > 4 ng/mL 30 3.339 0.741e15.040 0.116
BMI  24v/m2 and
WC < 90 cm
147 1 (reference)
BMI  24 kg/m2 and
WC  90 cm
28 1.210 0.458e3.199 0.701
BMI > 24 kg/m2 and
WC < 90 cm
69 1.049 0.546e2.014 0.886
BMI > 24 kg/m2 and
WC  90 cm
242 2.112 1.284e3.474 0.003
BMIZ body mass index; CIZ confidence interval; PSAZ pros-
tate-specific antigen; WCZwaist circumference.
a Adjusted for age in 10-year categories, PSA, and obesity
indices by multiple logistic regressions.
b Prostatic hyperplasia defined as prostate volume > 20 mL.Studies have shown that men with larger WC tend to have
more BPH surgeries and LUTS than men with normal WC.8,9
The BLSA study revealed those with large WC have an
increased likelihood of BPH (ORZ 1.17, 95% CI 0.77-3.09,
pZ 0.17).7 The Korean study conducted by Lee et al.16
showed PV was positively correlated with BMI and WC,
and WC was an independent risk factor for BPH (OR 3.37,
95% CI 1.08-10.5, pZ 0.037). The Chinese study found that
overweight and obese men have increased age-adjusted
risk of BPH.17 However, other studies of non-Asian individ-
uals demonstrated no association between BPH and
anthropometry.18,19 By age-adjusted logistic regression, our
data showed that men with BMI greater than 24 kg/m2, WC
 90 cm, and PSA greater than 4 ng/mL are associated with
a higher risk of developing prostatic hyperplasia (Table 3).
When we examine these factors by multiple logistic
regression to adjust the possible interfering effect between
factors, only large WC (OR 1.737, 95% CI 1.007-2.997,
pZ 0.047) and age can significantly increase the risk of BPH
independently; on the contrary, high PSA (OR 3.339, 95% CI
0.741-15.040, pZ 0.116) or BMI (OR 1.224, 95% CI 0.703-
2.131, pZ 0.475) were not independent risk factors (data
not shown in table). This suggests interactions between WC
and PSA or BMI, and emphasizes the role of large WC in
prostate growth.
There is no consensus about which anthropometric
measure(s) should be used to define obesity, including BMI,
WC, or the waist-to-hip ratio.20 To define obesity with only
one measure might not always be correct. A tall and fit man
may have a WC  90 cm and a normal BMI. A muscular man
may have a BMI < 24 kg/m2 and WC < 90 cm. We cross BMI
and WC status to regroup our population, including normal
(BMI  24 kg/m2 and WC < 90 cm, nZ 147, 30.2%), high WC
alone (BMI  24 kg/m2 and WC  90 cm, nZ 28, 5.8%), high
BMI alone (BMI > 24 kg/m2 and WC < 90 cm, nZ 69, 14.2%),
and abdominal overweight/obesity (BMI > 24 kg/m2 and WC
 90 cm, nZ 242, 49.8%). Then we repeat the multiple
logistic regression analysis using this new obesity index
(Table 4). It showed only abdominal overweight/obesity
(BMI > 24 kg/m2 and WC  90 cm) is an independent risk
factor of prostatic hyperplasia (OR 2.112, 95% CI 1.284-
3.474, pZ 0.003), whereas high serum PSA, high BMI alone,
or high WC alone are not. This result echoes that of Lee
et al.16 (BMI  25 kg/m2 and WC > 90 cm, OR of BPH: 4.88,
pZ 0.008) but we use more strict cutoff rules on BMI
(> 24 kg/m2 vs. 25 kg/m2) as different national standards
were applied. In the study by Lee et al.,16 the central
obesity group only has 30 men (20.5%) in the 146-patient
cohort and there was no one in the high-WC-alone group.
Our result suggests that when discussing the relationship
between obesity and prostate hyperplasia, we should not
simply use BMI or WC alone to define obesity. Clinically, in
men with high WC and high BMI, the risk of developing
prostatic hyperplasia is more than twofold in comparison
with men with normal WC and BMI. A reduction of WC and
BMI to normal levels is encouraged to avoid overgrowth of
the prostate gland.
By univariate age-adjusted logistic regression, our data
showed that men with PSA higher than 4 ng/mL have a five-
fold risk of developing BPH (OR 5.507, 95% CI 1.187-21.547,
pZ 0.028). Linear regression also confirmed that serum PSA
level is positively related with PV (p< 0.001, R2Z 0.197,
Waist circumference and BPH 167data not shown). However, when we take PSA, BMI, WC, and
age together into the multiple logistic regression analysis,
the effect of PSAwas reduced (OR 3.339, 95% CI 0.741-15.04)
and became nonsignificant (pZ 0.116). This finding is similar
to a previously published northern Taiwan clinic-based study,
which found that PSA is not related to prostate size,21 and
another southern Taiwan screening study in which it was
concluded that neither PSA, BMI, nor testosterone was
independently correlated with PV.22
Abdominal obesity was known to be associated with
a number of cardiovascular and hormonal responses,23
including the increase in renal venous pressure as well as
increased renin and aldosterone levels. Gat et al.24 observed
that the connection between obesity and prostatic hyper-
plasia is not only hormonal.24 They proposed that an
increased hydrostatic pressure impairs prostatic and testic-
ular venous return, leading to increased testicular testos-
terone level and prostate hydrostatic pressure, and together
contribute to the development of BPH. Cohen25 hypothe-
sized with the chronic venous congestion in obese men, the
prostate was exposed to elevated testosterone levels and
more inflammatory and oxidative stress, which stimulate
both stromal and epithelial cellular activity and lead to
prostatic hyperplasia.
This is the first study to provide the evidence that WC is
positively associated with PV in the Taiwanese population.
The study participants, who are men undergoing health
examinations, might reflect the true population better than
other clinic-based studies (which may include more symp-
tomatic patients). A limitation of this study is the absence
of testosterone-related data, which are not provided in the
health examination package. Thus, we cannot compare the
relationship between serum hormone level and the
anthropometric measures and PV. Further studies including
hormonal analysis are needed to evaluate the previously
mentioned mechanisms.
In this preliminary study, we find that only age andWC are
independent risk factors of BPH in Taiwanese men. Men with
WC  90 cm have 1.737-fold risk of prostatic overgrowth.
Further analysis showed that men with BMI > 24 kg/m2 and
WC  90 cm have a twofold risk of developing prostatic
hyperplasia.References
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